Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Unknown 3Terminated 3Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Transplantation, Autologous × Clear all
NCT05852717 2026-05-06

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Hoosier Cancer Research Network

Phase 2 Recruiting
32 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06463717 2024-06-24

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

First Affiliated Hospital of Zhejiang University

Recruiting
210 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡